Keytruda PBS for LC
MINISTER for Health Greg Hunt has announced the funding of immunotherapy medicine Keytruda (pembrolizumab) for first-line treatment of metastatic non-small cell lung cancer (NSCLC) to take effect 01 Nov.
Without PBS subsidy it would cost over $11,300 per script or $188,000 a year, Hunt said.
This indication-extension listing was recommended at the Jul 2018 Pharmaceutical Benefits Advisory Committee (PBAC) meeting.
See more at health.gov.au.